Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cordis US Corp.
With
Conor Medsystems
Non -inferiority in 8-month Major Adverse Cardiac Events (MACE) and in-segment late lumen loss at 9 months between the CoStar™ Paclitaxel-Eluting Coronary Stent System and the TAXUS™ Express2™ Drug Eluting Coronary Stent System for the treatment of a single de novo lesion per vessel in patients with single and multi-vessel coronary disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligible for percutaneous coronary intervention (PCI)
Documented stable or unstable angina pectoris (Class I, II, III or IV), documented ischemia, or documented silent ischemia
Documented LVEF ≥25% within the last 6 weeks.
Eligible for coronary artery bypass graft surgery (CABG)
You may not be if
Known sensitivity to paclitaxel or polymeric matrices: Translute or PLGA.
Planned treatment with any other PCI device in the target vessel(s).
MI within 72 hours prior to the index procedure
Patient is in cardiogenic shock
Cerebrovascular Accident (CVA) within the past 6 months
Acute or chronic renal dysfunction (creatinine \>2.0 mg/dl or \>150 µmol/L)
Contraindication to ASA or to clopidogrel
Thrombocytopenia
Active GI bleeding within past three months
Known allergy to stainless steel or cobalt chromium
Any prior true anaphylactic reaction to contrast agents
